down arrow

Mind Medicine (MindMed), Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA60255C8850
USD
12.43
0.37 (3.07%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

11.8012.54

52 Week

4.7014.43
Valuation
Technical
Day's Volume

CASH

1.2 M

Shareholding (Mar 2025)

FII

8.62%

Held by 68 FIIs

DII

76.72%

Held by 17 DIIs

Promoter

2.04%

How big is Mind Medicine (MindMed), Inc.?

22-Jun-2025

As of Jun 18, Mind Medicine (MindMed), Inc. has a market capitalization of 506.96 million and reported net sales of 0.00 million with a net profit of -77.62 million over the last four quarters. Shareholder's funds were 241.45 million, and total assets were 302.15 million.

As of Jun 18, Mind Medicine (MindMed), Inc. has a market capitalization of 506.96 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a consolidated net profit of -77.62 million during the same period.<BR><BR>As of Dec 24, the shareholder's funds amounted to 241.45 million, while total assets were reported at 302.15 million.

Read More

What does Mind Medicine (MindMed), Inc. do?

22-Jun-2025

Mind Medicine (MindMed), Inc. is a neuro-pharmaceutical company focused on developing psychedelic-inspired medicines for health and wellness. It has a market cap of approximately $506.96 million and reported a net profit loss of $23 million as of March 2025.

Overview: <BR>Mind Medicine (MindMed), Inc. is a neuro-pharmaceutical company that discovers, develops, and deploys psychedelic-inspired medicines to improve health, promote wellness, and alleviate suffering, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -23 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 506.96 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.85 <BR>Return on Equity: -46.73% <BR>Price to Book: 2.28<BR><BR>Contact Details: <BR>Address: 1166 Alberni Street, Suite 1604, VANCOUVER BC : V6E 3Z3 <BR>Tel: 1 604 7614689 <BR>Fax: 1 888 8483972 <BR>Website: http://broadwaymining.com/

Read More

Who are in the management team of Mind Medicine (MindMed), Inc.?

22-Jun-2025

As of March 2022, the management team of Mind Medicine (MindMed), Inc. includes Executive Chairman and Co-CEO Stephen Hurst, President and Director Miriam Wernli, and Co-CEO Jamon Rahn, along with independent directors Perry Dellelce, Stanley Glick, Bruce Linton, and Brigid Makes.

As of March 2022, the management team of Mind Medicine (MindMed), Inc. includes the following individuals:<BR><BR>- Mr. Stephen Hurst: Executive Chairman of the board, Co-Chief Executive Officer, Founder, and Secretary.<BR>- Ms. Miriam Wernli: President and Director.<BR>- Mr. Jamon Rahn: Co-Chief Executive Officer, Founder, and Director.<BR><BR>Additionally, the board of directors includes independent directors: Mr. Perry Dellelce, Dr. Stanley Glick, Mr. Bruce Linton, and Ms. Brigid Makes.

Read More

Is Mind Medicine (MindMed), Inc. technically bullish or bearish?

23-Sep-2025

As of September 19, 2025, Mind Medicine (MindMed), Inc. has a mildly bullish trend, supported by a bullish MACD and Bollinger Bands, despite some bearish signals from KST and Dow Theory, with the stock returning 37.07% year-to-date and 59.80% over the past year, outperforming the S&P 500.

As of 19 September 2025, the technical trend for Mind Medicine (MindMed), Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish signal from Bollinger Bands on both weekly and monthly timeframes. However, the KST indicates a mildly bearish trend on the monthly, and Dow Theory shows a mildly bearish stance on the weekly. <BR><BR>In terms of performance, the stock has returned 37.07% year-to-date and 59.80% over the past year, significantly outperforming the S&P 500, which returned 13.31% and 16.64% respectively in the same periods.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 714 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.76

stock-summary
Return on Equity

-66.23%

stock-summary
Price to Book

3.85

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-43 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
37.2%
0%
37.2%
6 Months
61.64%
0%
61.64%
1 Year
66.07%
0%
66.07%
2 Years
253.12%
0%
253.12%
3 Years
369.06%
0%
369.06%
4 Years
-55.21%
0%
-55.21%
5 Years
-49.47%
0%
-49.47%

Mind Medicine (MindMed), Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Mind Medicine (MindMed), Inc. technically bullish or bearish?

As of 19 September 2025, the technical trend for Mind Medicine (MindMed), Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish signal from Bollinger Bands on both weekly and monthly timeframes. However, the KST indicates a mildly bearish trend on the monthly, and Dow Theory shows a mildly bearish stance on the weekly. In terms of performance, the stock has returned 37.07% year-to-date and 59.80% over the past year, significantly outperforming the S&P 500, which returned 13.31% and 16.64% respectively in the same periods....

Read More

Is Mind Medicine (MindMed), Inc. technically bullish or bearish?

As of 19 September 2025, the technical trend for Mind Medicine (MindMed), Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating a positive momentum. The Bollinger Bands are also showing a mildly bullish trend on the weekly chart and bullish on the monthly chart. Moving averages on the daily timeframe are mildly bullish, supporting the overall positive sentiment. However, the KST indicates a bullish weekly stance but a mildly bearish monthly outlook, which introduces some caution. In terms of performance, the stock has returned 29.89% year-to-date and 43.26% over the past year, significantly outperforming the S&P 500, which has returned 13.31% and 16.64% respectively during the same periods. However, over longer time frames, such as 3 years and 5 years, the stock has underperformed the S&P 500. Overall, the current technical stance...

Read More

Is Mind Medicine (MindMed), Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for Mind Medicine (MindMed), Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands are bullish on both weekly and monthly time frames. Daily moving averages indicate a bullish stance. However, the KST shows a mildly bearish trend on a monthly basis, and the weekly OBV is mildly bullish, suggesting some mixed signals. In terms of returns, the stock has outperformed the S&P 500 year-to-date with a return of 36.21% compared to 12.22%, and over the past year with 55.92% against 17.14%. However, it has underperformed over the 3-year, 5-year, and 10-year periods. Overall, the current technical stance is mildly bullish, driven by strong weekly indicators but tempered by some monthly bearish signals....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-259.88%
EBIT to Interest (avg)
-61.49
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.85
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
66.48%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.64
EV to EBIT
-3.50
EV to EBITDA
-3.50
EV to Capital Employed
12.29
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-351.44%
ROE (Latest)
-46.73%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 28 Schemes (12.62%)

Foreign Institutions

Held by 68 Foreign Institutions (8.62%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -623.73% vs 79.73% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-40.90",
          "val2": "-24.50",
          "chgp": "-66.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.30",
          "val2": "0.50",
          "chgp": "360.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.20",
          "val2": "16.00",
          "chgp": "-113.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-42.70",
          "val2": "-5.90",
          "chgp": "-623.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -13.58% vs -68.49% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-103.40",
          "val2": "-90.70",
          "chgp": "-14.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-13.40",
          "val2": "-6.60",
          "chgp": "-103.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-108.70",
          "val2": "-95.70",
          "chgp": "-13.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-40.90
-24.50
-66.94%
Interest
2.30
0.50
360.00%
Exceptional Items
-2.20
16.00
-113.75%
Consolidate Net Profit
-42.70
-5.90
-623.73%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -623.73% vs 79.73% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-103.40
-90.70
-14.00%
Interest
2.30
0.00
Exceptional Items
-13.40
-6.60
-103.03%
Consolidate Net Profit
-108.70
-95.70
-13.58%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -13.58% vs -68.49% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Mind Medicine (MindMed), Inc. stock-summary
stock-summary
Mind Medicine (MindMed), Inc.
Pharmaceuticals & Biotechnology
Mind Medicine (MindMed) Inc., formerly Broadway Gold Mining Ltd., is a neuro-pharmaceutical company. The Company discovers, develops and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering. The Company addresses the opioid crisis by developing a non-hallucinogenic version of the psychedelic ibogaine.
Company Coordinates stock-summary
Company Details
1166 Alberni Street, Suite 1604 , VANCOUVER BC : V6E 3Z3
stock-summary
Tel: 1 604 7614689
stock-summary
http://broadwaymining.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."